Skip to main content
Internal Medicine
ALL Specialities
ALL Specialities
/
Internal Medicine
CME
COVID-19 Updates
Diseases & Conditions
Asthma
Diabetes
Musculoskeletal Disorders
Obesity
Pain
Rare Diseases
Subspecialties
Addiction Medicine
Adolescent Medicine
Cardiology
Critical Care
Dermatology
Endocrinology
Gastroenterology
Geriatrics
Hematology
Hepatology
Hospice & Palliative Medicine
Immunology
Infectious Diseases
Men's Health
Mental Health
Nephrology
Neurology
Oncology
Pulmonology
Rheumatology
Sleep Medicine
Transgender Health
Women's Health
Multimedia
Audio
Podcasts
Video
Business of Medicine
News
FDA approves alogliptin, alone and in combinations
Publish date:
January 28, 2013
a.ault@elsevier.com
Twitter
@aliciaault
Pages
« first
1
2
Recommended Reading
Ranbaxy Recalls Atorvastatin
MDedge Internal Medicine
PCSK9 Antibodies Safely Cut LDL in Phase II
MDedge Internal Medicine
Statins' Diabetogenic Impact Influenced by Underlying Risks
MDedge Internal Medicine
Fatty Liver Disease: The Silent Epidemic
MDedge Internal Medicine
Bariatric surgery cut vascular events in diabetes
MDedge Internal Medicine
FDA panel backs approval of canagliflozin for type 2 diabetes
MDedge Internal Medicine
How to prevent 1 million coronary events
MDedge Internal Medicine
Statins cut risk of hepatocellular carcinoma
MDedge Internal Medicine
Metabolic syndrome skews Oncotype DX reliability
MDedge Internal Medicine
HDL-raising: A good hypothesis gone bad
MDedge Internal Medicine
Diabetes
Endocrinology
All Specialties
